Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis

Catherine L. Skagen, Janice Jou, Adnan Said

Research output: Contribution to journalArticle

41 Scopus citations


Many transplant programs utilize liver grafts from hepatitis-B core antibody (HBcAb)-positive and hepatitis-B surface antigen (HBsAg)-negative donors. However, there is risk for de novo hepatitis B (DNH) in recipients of these grafts. We reviewed 26 studies reporting the rates of DNH in recipients receiving HBcAb-positive liver grafts. Four hundred and sixty-two donor-recipient pairs were included to evaluate the risk of DNH stratified by the recipient's immune status to hepatitis B and type of prophylactic therapy given, if any. The rate of DNH was highest (58%) in the stratum of hepatitis-B (HBV) naïve recipients who did not receive prophylaxis. In HBV naïve recipients, prophylactic therapy (lamivudine and/or hepatitis-B immunoglobulin - HBIG) reduced DNH to 11% (odds ratio [OR]=11.1, 95% CI 4.98-25, p

Original languageEnglish (US)
JournalClinical Transplantation
Issue number3
Publication statusPublished - May 2011
Externally publishedYes



  • de novo hepatitis
  • Hepatitis B
  • Hepatitis-B core antibody positive donor
  • Liver transplantation
  • Outcomes

ASJC Scopus subject areas

  • Transplantation

Cite this